» Articles » PMID: 37426243

Comparative Saturation Binding Analysis of Cu-Labeled Somatostatin Analogues Using Cell Homogenates and Intact Cells

Overview
Journal ACS Omega
Specialty Chemistry
Date 2023 Jul 10
PMID 37426243
Authors
Affiliations
Soon will be listed here.
Abstract

The development of novel ligands for G-protein-coupled receptors (GPCRs) typically entails the characterization of their binding affinity, which is often performed with radioligands in a competition or saturation binding assay format. Since GPCRs are transmembrane proteins, receptor samples for binding assays are prepared from tissue sections, cell membranes, cell homogenates, or intact cells. As part of our investigations on modulating the pharmacokinetics of radiolabeled peptides for improved theranostic targeting of neuroendocrine tumors with a high abundance of the somatostatin receptor sub-type 2 (SST), we characterized a series of Cu-labeled [Tyr]octreotate (TATE) derivatives in vitro in saturation binding assays. Herein, we report on the SST binding parameters measured toward intact mouse pheochromocytoma cells and corresponding cell homogenates and discuss the observed differences taking the physiology of SST and GPCRs in general into account. Furthermore, we point out method-specific advantages and limitations.

Citing Articles

The heterobivalent (SSTR2/albumin) radioligand [Cu]Cu-NODAGA-cLAB4-TATE enables efficient somatostatin receptor radionuclide theranostics.

Ullrich M, Wodtke R, Brandt F, Freudenberg R, Kotzerke J, Richter S Theranostics. 2024; 14(14):5371-5387.

PMID: 39310112 PMC: 11413788. DOI: 10.7150/thno.100091.

References
1.
Mansi R, Plas P, Vauquelin G, Fani M . Distinct In Vitro Binding Profile of the Somatostatin Receptor Subtype 2 Antagonist [Lu]Lu-OPS201 Compared to the Agonist [Lu]Lu-DOTA-TATE. Pharmaceuticals (Basel). 2021; 14(12). PMC: 8706879. DOI: 10.3390/ph14121265. View

2.
Schottelius M, Reubi J, Eltschinger V, Schwaiger M, Wester H . N-terminal sugar conjugation and C-terminal Thr-for-Thr(ol) exchange in radioiodinated Tyr3-octreotide: effect on cellular ligand trafficking in vitro and tumor accumulation in vivo. J Med Chem. 2005; 48(8):2778-89. DOI: 10.1021/jm040794i. View

3.
Gerwins P, Nordstedt C, Fredholm B . Characterization of adenosine A1 receptors in intact DDT1 MF-2 smooth muscle cells. Mol Pharmacol. 1990; 38(5):660-6. View

4.
Maguire J, Kuc R, Davenport A . Radioligand binding assays and their analysis. Methods Mol Biol. 2012; 897:31-77. DOI: 10.1007/978-1-61779-909-9_3. View

5.
Sykes D, Stoddart L, Kilpatrick L, Hill S . Binding kinetics of ligands acting at GPCRs. Mol Cell Endocrinol. 2019; 485:9-19. PMC: 6406023. DOI: 10.1016/j.mce.2019.01.018. View